Many have also said that HRSA has insufficient resources to provide oversight of both manufacturers and covered entities. So I believe that We need to increase transparency within the 340B program while ensuring that there's not an undue administrative burden. Ms. Rosenberg, what concerns about transparency and ability to provide oversight has the GAO identified? So, as you noted, there aren't requirements for entities to specify how they use the revenue from the 340B program, what it's towards. (02:38–02:48)
CLAIM
Asserts the need for increased transparency in the 340B program without adding excessive administrative burdens.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
